十三五健康产业科技创新规划印发:重点开发8-10个原创性新药产品

2017-06-16 佚名 证券时报

科技部网站14日消息,科技部、发改委、工信部、国家卫生计生委、体育总局、食品药品监管总局印发《“十三五”健康产业科技创新专项规划》,规划提出,以保障全人群、全生命周期的健康需求为核心,重点发展创新药物、医疗器械、健康产品等三类产品,引领发展以“精准化、数字化、智能化、一体化”为方向的新型医疗健康服务模式,着力打造科技创新平台、公共服务云平台等支撑平台,构建全链条、竞争力强的产业科技支撑体系,建设一

科技部网站14日消息,科技部、发改委、工信部、国家卫生计生委、体育总局、食品药品监管总局印发《“十三五”健康产业科技创新专项规划》,规划提出,以保障全人群、全生命周期的健康需求为核心,重点发展创新药物、医疗器械、健康产品等三类产品,引领发展以“精准化、数字化、智能化、一体化”为方向的新型医疗健康服务模式,着力打造科技创新平台、公共服务云平台等支撑平台,构建全链条、竞争力强的产业科技支撑体系,建设一批健康产业专业化园区和综合示范区,培育一批具有国际竞争力的健康产业优势品牌企业,助推健康产业创新发展。

重点突破新药发现、高端医疗器械、个性化健康干预等关键科技问题,攻克10-15项重大关键共性技术,发展20-30项前沿性技术。

重点开发8-10个原创性新药产品、10-20项前沿创新医疗器械、50种高端健康产品。

积极推进新型健康产业培育,引领发展新型医疗健康服务,培育5-10个有国际影响力的健康品牌企业集群,建立10-15个健康产业专业化园区。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1741065, encodeId=844b1e41065b5, content=<a href='/topic/show?id=89f12e726ee' target=_blank style='color:#2F92EE;'>#健康产业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27726, encryptionId=89f12e726ee, topicName=健康产业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f0d34859827, createdName=12498e0fm89暂无昵称, createdTime=Tue Oct 31 08:11:00 CST 2017, time=2017-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1672470, encodeId=85cb16e247080, content=<a href='/topic/show?id=60819060283' target=_blank style='color:#2F92EE;'>#规划#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90602, encryptionId=60819060283, topicName=规划)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=676926912123, createdName=respect, createdTime=Sun Dec 10 08:11:00 CST 2017, time=2017-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907304, encodeId=b89b190e30488, content=<a href='/topic/show?id=85fe35655ea' target=_blank style='color:#2F92EE;'>#十三五#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35655, encryptionId=85fe35655ea, topicName=十三五)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri Nov 03 19:11:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285366, encodeId=435d128536627, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sun Jun 18 02:11:00 CST 2017, time=2017-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574307, encodeId=368215e43070a, content=<a href='/topic/show?id=3c2c586e23f' target=_blank style='color:#2F92EE;'>#新规#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58672, encryptionId=3c2c586e23f, topicName=新规)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2ca16016783, createdName=xsm923, createdTime=Sun Jun 18 02:11:00 CST 2017, time=2017-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1617628, encodeId=be4d161e62803, content=<a href='/topic/show?id=9e9ce4939a5' target=_blank style='color:#2F92EE;'>#科技创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74939, encryptionId=9e9ce4939a5, topicName=科技创新)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2cf19789758, createdName=12498bf3m31暂无昵称, createdTime=Sun Jun 18 02:11:00 CST 2017, time=2017-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=211542, encodeId=2f8721154253, content=不错的,学习了!谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdqKgfW3nMpOkC3jXxiaW2po0PtglY5ZuVjERqKADW4HyMI8bcZXWlKgH7tEP9ULBoBzuQMibia4pr1s9rQPqLvqQJ/0, createdBy=e8c02060444, createdName=中医痴, createdTime=Fri Jun 16 12:42:06 CST 2017, time=2017-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=211518, encodeId=b5b821151826, content=杜绝山寨版假药的生产, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/05/25/aee510ed68ce4736e9fe4ec7d03c01b1.jpg, createdBy=ce892064652, createdName=楠博One, createdTime=Fri Jun 16 11:20:22 CST 2017, time=2017-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=211516, encodeId=076d211516a5, content=重点突破新药发现、高端医疗器械、个性化健康干预等关键科技问题, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Fri Jun 16 11:18:06 CST 2017, time=2017-06-16, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1741065, encodeId=844b1e41065b5, content=<a href='/topic/show?id=89f12e726ee' target=_blank style='color:#2F92EE;'>#健康产业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27726, encryptionId=89f12e726ee, topicName=健康产业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f0d34859827, createdName=12498e0fm89暂无昵称, createdTime=Tue Oct 31 08:11:00 CST 2017, time=2017-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1672470, encodeId=85cb16e247080, content=<a href='/topic/show?id=60819060283' target=_blank style='color:#2F92EE;'>#规划#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90602, encryptionId=60819060283, topicName=规划)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=676926912123, createdName=respect, createdTime=Sun Dec 10 08:11:00 CST 2017, time=2017-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907304, encodeId=b89b190e30488, content=<a href='/topic/show?id=85fe35655ea' target=_blank style='color:#2F92EE;'>#十三五#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35655, encryptionId=85fe35655ea, topicName=十三五)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri Nov 03 19:11:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285366, encodeId=435d128536627, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sun Jun 18 02:11:00 CST 2017, time=2017-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574307, encodeId=368215e43070a, content=<a href='/topic/show?id=3c2c586e23f' target=_blank style='color:#2F92EE;'>#新规#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58672, encryptionId=3c2c586e23f, topicName=新规)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2ca16016783, createdName=xsm923, createdTime=Sun Jun 18 02:11:00 CST 2017, time=2017-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1617628, encodeId=be4d161e62803, content=<a href='/topic/show?id=9e9ce4939a5' target=_blank style='color:#2F92EE;'>#科技创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74939, encryptionId=9e9ce4939a5, topicName=科技创新)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2cf19789758, createdName=12498bf3m31暂无昵称, createdTime=Sun Jun 18 02:11:00 CST 2017, time=2017-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=211542, encodeId=2f8721154253, content=不错的,学习了!谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdqKgfW3nMpOkC3jXxiaW2po0PtglY5ZuVjERqKADW4HyMI8bcZXWlKgH7tEP9ULBoBzuQMibia4pr1s9rQPqLvqQJ/0, createdBy=e8c02060444, createdName=中医痴, createdTime=Fri Jun 16 12:42:06 CST 2017, time=2017-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=211518, encodeId=b5b821151826, content=杜绝山寨版假药的生产, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/05/25/aee510ed68ce4736e9fe4ec7d03c01b1.jpg, createdBy=ce892064652, createdName=楠博One, createdTime=Fri Jun 16 11:20:22 CST 2017, time=2017-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=211516, encodeId=076d211516a5, content=重点突破新药发现、高端医疗器械、个性化健康干预等关键科技问题, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Fri Jun 16 11:18:06 CST 2017, time=2017-06-16, status=1, ipAttribution=)]
    2017-12-10 respect
  3. [GetPortalCommentsPageByObjectIdResponse(id=1741065, encodeId=844b1e41065b5, content=<a href='/topic/show?id=89f12e726ee' target=_blank style='color:#2F92EE;'>#健康产业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27726, encryptionId=89f12e726ee, topicName=健康产业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f0d34859827, createdName=12498e0fm89暂无昵称, createdTime=Tue Oct 31 08:11:00 CST 2017, time=2017-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1672470, encodeId=85cb16e247080, content=<a href='/topic/show?id=60819060283' target=_blank style='color:#2F92EE;'>#规划#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90602, encryptionId=60819060283, topicName=规划)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=676926912123, createdName=respect, createdTime=Sun Dec 10 08:11:00 CST 2017, time=2017-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907304, encodeId=b89b190e30488, content=<a href='/topic/show?id=85fe35655ea' target=_blank style='color:#2F92EE;'>#十三五#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35655, encryptionId=85fe35655ea, topicName=十三五)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri Nov 03 19:11:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285366, encodeId=435d128536627, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sun Jun 18 02:11:00 CST 2017, time=2017-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574307, encodeId=368215e43070a, content=<a href='/topic/show?id=3c2c586e23f' target=_blank style='color:#2F92EE;'>#新规#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58672, encryptionId=3c2c586e23f, topicName=新规)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2ca16016783, createdName=xsm923, createdTime=Sun Jun 18 02:11:00 CST 2017, time=2017-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1617628, encodeId=be4d161e62803, content=<a href='/topic/show?id=9e9ce4939a5' target=_blank style='color:#2F92EE;'>#科技创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74939, encryptionId=9e9ce4939a5, topicName=科技创新)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2cf19789758, createdName=12498bf3m31暂无昵称, createdTime=Sun Jun 18 02:11:00 CST 2017, time=2017-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=211542, encodeId=2f8721154253, content=不错的,学习了!谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdqKgfW3nMpOkC3jXxiaW2po0PtglY5ZuVjERqKADW4HyMI8bcZXWlKgH7tEP9ULBoBzuQMibia4pr1s9rQPqLvqQJ/0, createdBy=e8c02060444, createdName=中医痴, createdTime=Fri Jun 16 12:42:06 CST 2017, time=2017-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=211518, encodeId=b5b821151826, content=杜绝山寨版假药的生产, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/05/25/aee510ed68ce4736e9fe4ec7d03c01b1.jpg, createdBy=ce892064652, createdName=楠博One, createdTime=Fri Jun 16 11:20:22 CST 2017, time=2017-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=211516, encodeId=076d211516a5, content=重点突破新药发现、高端医疗器械、个性化健康干预等关键科技问题, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Fri Jun 16 11:18:06 CST 2017, time=2017-06-16, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1741065, encodeId=844b1e41065b5, content=<a href='/topic/show?id=89f12e726ee' target=_blank style='color:#2F92EE;'>#健康产业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27726, encryptionId=89f12e726ee, topicName=健康产业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f0d34859827, createdName=12498e0fm89暂无昵称, createdTime=Tue Oct 31 08:11:00 CST 2017, time=2017-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1672470, encodeId=85cb16e247080, content=<a href='/topic/show?id=60819060283' target=_blank style='color:#2F92EE;'>#规划#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90602, encryptionId=60819060283, topicName=规划)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=676926912123, createdName=respect, createdTime=Sun Dec 10 08:11:00 CST 2017, time=2017-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907304, encodeId=b89b190e30488, content=<a href='/topic/show?id=85fe35655ea' target=_blank style='color:#2F92EE;'>#十三五#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35655, encryptionId=85fe35655ea, topicName=十三五)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri Nov 03 19:11:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285366, encodeId=435d128536627, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sun Jun 18 02:11:00 CST 2017, time=2017-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574307, encodeId=368215e43070a, content=<a href='/topic/show?id=3c2c586e23f' target=_blank style='color:#2F92EE;'>#新规#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58672, encryptionId=3c2c586e23f, topicName=新规)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2ca16016783, createdName=xsm923, createdTime=Sun Jun 18 02:11:00 CST 2017, time=2017-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1617628, encodeId=be4d161e62803, content=<a href='/topic/show?id=9e9ce4939a5' target=_blank style='color:#2F92EE;'>#科技创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74939, encryptionId=9e9ce4939a5, topicName=科技创新)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2cf19789758, createdName=12498bf3m31暂无昵称, createdTime=Sun Jun 18 02:11:00 CST 2017, time=2017-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=211542, encodeId=2f8721154253, content=不错的,学习了!谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdqKgfW3nMpOkC3jXxiaW2po0PtglY5ZuVjERqKADW4HyMI8bcZXWlKgH7tEP9ULBoBzuQMibia4pr1s9rQPqLvqQJ/0, createdBy=e8c02060444, createdName=中医痴, createdTime=Fri Jun 16 12:42:06 CST 2017, time=2017-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=211518, encodeId=b5b821151826, content=杜绝山寨版假药的生产, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/05/25/aee510ed68ce4736e9fe4ec7d03c01b1.jpg, createdBy=ce892064652, createdName=楠博One, createdTime=Fri Jun 16 11:20:22 CST 2017, time=2017-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=211516, encodeId=076d211516a5, content=重点突破新药发现、高端医疗器械、个性化健康干预等关键科技问题, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Fri Jun 16 11:18:06 CST 2017, time=2017-06-16, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1741065, encodeId=844b1e41065b5, content=<a href='/topic/show?id=89f12e726ee' target=_blank style='color:#2F92EE;'>#健康产业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27726, encryptionId=89f12e726ee, topicName=健康产业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f0d34859827, createdName=12498e0fm89暂无昵称, createdTime=Tue Oct 31 08:11:00 CST 2017, time=2017-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1672470, encodeId=85cb16e247080, content=<a href='/topic/show?id=60819060283' target=_blank style='color:#2F92EE;'>#规划#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90602, encryptionId=60819060283, topicName=规划)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=676926912123, createdName=respect, createdTime=Sun Dec 10 08:11:00 CST 2017, time=2017-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907304, encodeId=b89b190e30488, content=<a href='/topic/show?id=85fe35655ea' target=_blank style='color:#2F92EE;'>#十三五#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35655, encryptionId=85fe35655ea, topicName=十三五)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri Nov 03 19:11:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285366, encodeId=435d128536627, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sun Jun 18 02:11:00 CST 2017, time=2017-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574307, encodeId=368215e43070a, content=<a href='/topic/show?id=3c2c586e23f' target=_blank style='color:#2F92EE;'>#新规#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58672, encryptionId=3c2c586e23f, topicName=新规)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2ca16016783, createdName=xsm923, createdTime=Sun Jun 18 02:11:00 CST 2017, time=2017-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1617628, encodeId=be4d161e62803, content=<a href='/topic/show?id=9e9ce4939a5' target=_blank style='color:#2F92EE;'>#科技创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74939, encryptionId=9e9ce4939a5, topicName=科技创新)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2cf19789758, createdName=12498bf3m31暂无昵称, createdTime=Sun Jun 18 02:11:00 CST 2017, time=2017-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=211542, encodeId=2f8721154253, content=不错的,学习了!谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdqKgfW3nMpOkC3jXxiaW2po0PtglY5ZuVjERqKADW4HyMI8bcZXWlKgH7tEP9ULBoBzuQMibia4pr1s9rQPqLvqQJ/0, createdBy=e8c02060444, createdName=中医痴, createdTime=Fri Jun 16 12:42:06 CST 2017, time=2017-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=211518, encodeId=b5b821151826, content=杜绝山寨版假药的生产, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/05/25/aee510ed68ce4736e9fe4ec7d03c01b1.jpg, createdBy=ce892064652, createdName=楠博One, createdTime=Fri Jun 16 11:20:22 CST 2017, time=2017-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=211516, encodeId=076d211516a5, content=重点突破新药发现、高端医疗器械、个性化健康干预等关键科技问题, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Fri Jun 16 11:18:06 CST 2017, time=2017-06-16, status=1, ipAttribution=)]
    2017-06-18 xsm923
  6. [GetPortalCommentsPageByObjectIdResponse(id=1741065, encodeId=844b1e41065b5, content=<a href='/topic/show?id=89f12e726ee' target=_blank style='color:#2F92EE;'>#健康产业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27726, encryptionId=89f12e726ee, topicName=健康产业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f0d34859827, createdName=12498e0fm89暂无昵称, createdTime=Tue Oct 31 08:11:00 CST 2017, time=2017-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1672470, encodeId=85cb16e247080, content=<a href='/topic/show?id=60819060283' target=_blank style='color:#2F92EE;'>#规划#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90602, encryptionId=60819060283, topicName=规划)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=676926912123, createdName=respect, createdTime=Sun Dec 10 08:11:00 CST 2017, time=2017-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907304, encodeId=b89b190e30488, content=<a href='/topic/show?id=85fe35655ea' target=_blank style='color:#2F92EE;'>#十三五#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35655, encryptionId=85fe35655ea, topicName=十三五)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri Nov 03 19:11:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285366, encodeId=435d128536627, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sun Jun 18 02:11:00 CST 2017, time=2017-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574307, encodeId=368215e43070a, content=<a href='/topic/show?id=3c2c586e23f' target=_blank style='color:#2F92EE;'>#新规#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58672, encryptionId=3c2c586e23f, topicName=新规)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2ca16016783, createdName=xsm923, createdTime=Sun Jun 18 02:11:00 CST 2017, time=2017-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1617628, encodeId=be4d161e62803, content=<a href='/topic/show?id=9e9ce4939a5' target=_blank style='color:#2F92EE;'>#科技创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74939, encryptionId=9e9ce4939a5, topicName=科技创新)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2cf19789758, createdName=12498bf3m31暂无昵称, createdTime=Sun Jun 18 02:11:00 CST 2017, time=2017-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=211542, encodeId=2f8721154253, content=不错的,学习了!谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdqKgfW3nMpOkC3jXxiaW2po0PtglY5ZuVjERqKADW4HyMI8bcZXWlKgH7tEP9ULBoBzuQMibia4pr1s9rQPqLvqQJ/0, createdBy=e8c02060444, createdName=中医痴, createdTime=Fri Jun 16 12:42:06 CST 2017, time=2017-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=211518, encodeId=b5b821151826, content=杜绝山寨版假药的生产, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/05/25/aee510ed68ce4736e9fe4ec7d03c01b1.jpg, createdBy=ce892064652, createdName=楠博One, createdTime=Fri Jun 16 11:20:22 CST 2017, time=2017-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=211516, encodeId=076d211516a5, content=重点突破新药发现、高端医疗器械、个性化健康干预等关键科技问题, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Fri Jun 16 11:18:06 CST 2017, time=2017-06-16, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1741065, encodeId=844b1e41065b5, content=<a href='/topic/show?id=89f12e726ee' target=_blank style='color:#2F92EE;'>#健康产业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27726, encryptionId=89f12e726ee, topicName=健康产业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f0d34859827, createdName=12498e0fm89暂无昵称, createdTime=Tue Oct 31 08:11:00 CST 2017, time=2017-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1672470, encodeId=85cb16e247080, content=<a href='/topic/show?id=60819060283' target=_blank style='color:#2F92EE;'>#规划#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90602, encryptionId=60819060283, topicName=规划)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=676926912123, createdName=respect, createdTime=Sun Dec 10 08:11:00 CST 2017, time=2017-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907304, encodeId=b89b190e30488, content=<a href='/topic/show?id=85fe35655ea' target=_blank style='color:#2F92EE;'>#十三五#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35655, encryptionId=85fe35655ea, topicName=十三五)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri Nov 03 19:11:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285366, encodeId=435d128536627, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sun Jun 18 02:11:00 CST 2017, time=2017-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574307, encodeId=368215e43070a, content=<a href='/topic/show?id=3c2c586e23f' target=_blank style='color:#2F92EE;'>#新规#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58672, encryptionId=3c2c586e23f, topicName=新规)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2ca16016783, createdName=xsm923, createdTime=Sun Jun 18 02:11:00 CST 2017, time=2017-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1617628, encodeId=be4d161e62803, content=<a href='/topic/show?id=9e9ce4939a5' target=_blank style='color:#2F92EE;'>#科技创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74939, encryptionId=9e9ce4939a5, topicName=科技创新)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2cf19789758, createdName=12498bf3m31暂无昵称, createdTime=Sun Jun 18 02:11:00 CST 2017, time=2017-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=211542, encodeId=2f8721154253, content=不错的,学习了!谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdqKgfW3nMpOkC3jXxiaW2po0PtglY5ZuVjERqKADW4HyMI8bcZXWlKgH7tEP9ULBoBzuQMibia4pr1s9rQPqLvqQJ/0, createdBy=e8c02060444, createdName=中医痴, createdTime=Fri Jun 16 12:42:06 CST 2017, time=2017-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=211518, encodeId=b5b821151826, content=杜绝山寨版假药的生产, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/05/25/aee510ed68ce4736e9fe4ec7d03c01b1.jpg, createdBy=ce892064652, createdName=楠博One, createdTime=Fri Jun 16 11:20:22 CST 2017, time=2017-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=211516, encodeId=076d211516a5, content=重点突破新药发现、高端医疗器械、个性化健康干预等关键科技问题, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Fri Jun 16 11:18:06 CST 2017, time=2017-06-16, status=1, ipAttribution=)]
    2017-06-16 中医痴

    不错的,学习了!谢谢分享!

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1741065, encodeId=844b1e41065b5, content=<a href='/topic/show?id=89f12e726ee' target=_blank style='color:#2F92EE;'>#健康产业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27726, encryptionId=89f12e726ee, topicName=健康产业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f0d34859827, createdName=12498e0fm89暂无昵称, createdTime=Tue Oct 31 08:11:00 CST 2017, time=2017-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1672470, encodeId=85cb16e247080, content=<a href='/topic/show?id=60819060283' target=_blank style='color:#2F92EE;'>#规划#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90602, encryptionId=60819060283, topicName=规划)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=676926912123, createdName=respect, createdTime=Sun Dec 10 08:11:00 CST 2017, time=2017-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907304, encodeId=b89b190e30488, content=<a href='/topic/show?id=85fe35655ea' target=_blank style='color:#2F92EE;'>#十三五#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35655, encryptionId=85fe35655ea, topicName=十三五)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri Nov 03 19:11:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285366, encodeId=435d128536627, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sun Jun 18 02:11:00 CST 2017, time=2017-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574307, encodeId=368215e43070a, content=<a href='/topic/show?id=3c2c586e23f' target=_blank style='color:#2F92EE;'>#新规#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58672, encryptionId=3c2c586e23f, topicName=新规)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2ca16016783, createdName=xsm923, createdTime=Sun Jun 18 02:11:00 CST 2017, time=2017-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1617628, encodeId=be4d161e62803, content=<a href='/topic/show?id=9e9ce4939a5' target=_blank style='color:#2F92EE;'>#科技创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74939, encryptionId=9e9ce4939a5, topicName=科技创新)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2cf19789758, createdName=12498bf3m31暂无昵称, createdTime=Sun Jun 18 02:11:00 CST 2017, time=2017-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=211542, encodeId=2f8721154253, content=不错的,学习了!谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdqKgfW3nMpOkC3jXxiaW2po0PtglY5ZuVjERqKADW4HyMI8bcZXWlKgH7tEP9ULBoBzuQMibia4pr1s9rQPqLvqQJ/0, createdBy=e8c02060444, createdName=中医痴, createdTime=Fri Jun 16 12:42:06 CST 2017, time=2017-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=211518, encodeId=b5b821151826, content=杜绝山寨版假药的生产, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/05/25/aee510ed68ce4736e9fe4ec7d03c01b1.jpg, createdBy=ce892064652, createdName=楠博One, createdTime=Fri Jun 16 11:20:22 CST 2017, time=2017-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=211516, encodeId=076d211516a5, content=重点突破新药发现、高端医疗器械、个性化健康干预等关键科技问题, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Fri Jun 16 11:18:06 CST 2017, time=2017-06-16, status=1, ipAttribution=)]
    2017-06-16 楠博One

    杜绝山寨版假药的生产

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1741065, encodeId=844b1e41065b5, content=<a href='/topic/show?id=89f12e726ee' target=_blank style='color:#2F92EE;'>#健康产业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27726, encryptionId=89f12e726ee, topicName=健康产业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f0d34859827, createdName=12498e0fm89暂无昵称, createdTime=Tue Oct 31 08:11:00 CST 2017, time=2017-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1672470, encodeId=85cb16e247080, content=<a href='/topic/show?id=60819060283' target=_blank style='color:#2F92EE;'>#规划#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90602, encryptionId=60819060283, topicName=规划)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=676926912123, createdName=respect, createdTime=Sun Dec 10 08:11:00 CST 2017, time=2017-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907304, encodeId=b89b190e30488, content=<a href='/topic/show?id=85fe35655ea' target=_blank style='color:#2F92EE;'>#十三五#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35655, encryptionId=85fe35655ea, topicName=十三五)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri Nov 03 19:11:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285366, encodeId=435d128536627, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sun Jun 18 02:11:00 CST 2017, time=2017-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574307, encodeId=368215e43070a, content=<a href='/topic/show?id=3c2c586e23f' target=_blank style='color:#2F92EE;'>#新规#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58672, encryptionId=3c2c586e23f, topicName=新规)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2ca16016783, createdName=xsm923, createdTime=Sun Jun 18 02:11:00 CST 2017, time=2017-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1617628, encodeId=be4d161e62803, content=<a href='/topic/show?id=9e9ce4939a5' target=_blank style='color:#2F92EE;'>#科技创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74939, encryptionId=9e9ce4939a5, topicName=科技创新)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2cf19789758, createdName=12498bf3m31暂无昵称, createdTime=Sun Jun 18 02:11:00 CST 2017, time=2017-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=211542, encodeId=2f8721154253, content=不错的,学习了!谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdqKgfW3nMpOkC3jXxiaW2po0PtglY5ZuVjERqKADW4HyMI8bcZXWlKgH7tEP9ULBoBzuQMibia4pr1s9rQPqLvqQJ/0, createdBy=e8c02060444, createdName=中医痴, createdTime=Fri Jun 16 12:42:06 CST 2017, time=2017-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=211518, encodeId=b5b821151826, content=杜绝山寨版假药的生产, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/05/25/aee510ed68ce4736e9fe4ec7d03c01b1.jpg, createdBy=ce892064652, createdName=楠博One, createdTime=Fri Jun 16 11:20:22 CST 2017, time=2017-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=211516, encodeId=076d211516a5, content=重点突破新药发现、高端医疗器械、个性化健康干预等关键科技问题, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Fri Jun 16 11:18:06 CST 2017, time=2017-06-16, status=1, ipAttribution=)]
    2017-06-16 lyh994

    重点突破新药发现、高端医疗器械、个性化健康干预等关键科技问题

    0

相关资讯

国务院定调!严控三级医院门诊规模!医生收入或将下降!

日前,国务院印发《“十三五”卫生与健康规划》(下称规划),对“十三五”时期我国卫生发展进行规划部署。“十三五”时期,我国将严控三级医院普通门诊规模,并建立以控制不合理费用为重点的内审制度,规范医务人员医疗卫生服务行为。严控三级医院门诊规模!鼓励二级以上医院成立全科医学科。 值得注意的是,《规划》再次强调了各类医疗机构诊疗服务功能定位范围,尤其是大医院的职责,除了上述控制三级医院普通门诊规

“十三五”肺结核防治规划:治疗需成功率需达90%

2月16日,国务院办公厅印发的《“十三五”全国结核病防治规划》(下称《规划》)在中国政府网对外公布。《规划》要求,“十三五”期间,肺结核患者和疑似患者的报告到位率要达到95%以上,治疗成功率需达到90%以上。

中国十三五期间将推动中药治疗AIDS

1月19日国务院办公厅公开发布了《中国遏制与防治艾滋病“十三五”行动计划》,其中计划将采用传统中药(TCM)治疗更多的AIDS病人,部分原因是为了增加TCM在中国医疗系统中的使用,属于中国国务院应对HIV/AIDS的“十三五”行动计划中的一部分。 国务院官网的公告表明采用TCM治疗的AIDS病人的数量将为2015年的两倍。这个计划概述了中医

十三五时期,三级医院医生收入或将下降?

“十三五”时期,我国将严控三级医院普通门诊规模,并建立以控制不合理费用为重点的内审制度,规范医务人员医疗卫生服务行为。严控三级医院门诊规模!鼓励二级以上医院成立全科医学科值得注意的是,《规划》再次强调了各类医疗机构诊疗服务功能定位范围,尤其是大医院的职责,除了上述控制三级医院普通门诊规模等内容外,还提出要由基层医疗卫生机构逐步承担公立医院的普通门诊、稳定期和恢复期康复以及慢性病护理等服务。鼓励二级

国务院通过!十三五药品安全规划,发了!

昨日(2月3日),农历新年的第一个工作日,国务院总理李克强主持召开国务院常务会议,正式通过“十三五”国家食品和药品安全两个规划。▍十三五昨日公开的规划内容主要提及三方面内容:一是强化全过程监管。落实地方尤其是县级政府保障食品安全责任,加大对校园、小摊贩等重点区域和对象的日常监管,深入开展农药兽药残留等源头治理,重拳整治违法添加等行为,严防发生系统性风险。强化药品临床试验数据真实性监督,加快推进药品

“十三五”老年人健康服务将升级

国家卫生计生委、国家发改委、民政部、财政部、中国残疾人联合会、全国老龄工作委员会办公室等13部门近日联合印发《“十三五”健康老龄化规划》,要求在“十三五”期间,建立覆盖城乡老年人的基本医疗卫生制度,为老年人提供综合连续的整合型服务。